Advanced Renal Cell Carcinoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Advanced Renal Cell Carcinoma Treatment Landscape

Ono Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis

Novartis AG
Merck & Co., Inc.
Eisai Co., Ltd.
Chugai Pharmaceutical Co., Ltd.
Bristol Myers Squibb Company
Bayer AG
Pfizer Inc.
AbbVie Inc.
Teva Pharmaceuticals Industries Ltd.

Browse Key Market Insights with Data Illustration:

Advanced Renal Cell Carcinoma Treatment Market Forecast Report 2036

In the News

Bristol Myers Squibb Company and Exelixis, Inc. reported three-year follow-up results from the Phase 3 CheckMate-9ER trial. Compared to sunitinib, Opdivo (nivolumab) and CABOMETYX (cabozantinib) have demonstrated sustained survival and response rates when used as a first-line treatment for advanced renal cell carcinoma (RCC).
Merck & Co., Inc’s anti-PD-1 therapy KEYTRUDA has been approved by FDA for use as adjuvant therapy in patients with renal cell carcinoma (RCC) at intermediate-high or high recurrence risk following nephrectomy, or following nephrectomy and metastatic resection.

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of advanced renal cell carcinoma treatment is assessed at USD 6.67 Billion.

The advanced renal cell carcinoma treatment market size was valued at USD 6.34 Billion in 2023 and is set to reach USD 13.04 Billion by the end of 2036, registering around 5.7% CAGR during the forecast period i.e., between 2024-2036. Growing proportion of geriatric population, worldwide increasing ratio of smoking, and an upsurge in hypertension are the major factors driving the market growth.

North America is projected to dominate majority industry share by 2036, attributed to increasing prevalence of renal cell carcinoma and other cancers in the region.

Ono Pharmaceutical Co., Ltd., Novartis AG, Merck & Co., Inc., Eisai Co., Ltd., Chugai Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Bayer AG, Pfizer Inc., AbbVie Inc., Teva Pharmaceuticals Industries Ltd.

Advanced Renal Cell Carcinoma Treatment Market - Top Companies and Manufacturers

Companies Dominating the Advanced Renal Cell Carcinoma Treatment Landscape

Browse Key Market Insights with Data Illustration:

In the News

Frequently Asked Questions (FAQ)

How much is the advanced renal cell carcinoma treatment market worth?

Why is the demand for advanced renal cell carcinoma treatment growing?

Which region dominated the majority of advanced renal cell carcinoma treatment industry share?

Who are the top advanced renal cell carcinoma treatment companies?